...
首页> 外文期刊>Medicine. >Clinicopathological analysis of IgA nephropathy combined with other glomerular diseases
【24h】

Clinicopathological analysis of IgA nephropathy combined with other glomerular diseases

机译:IgA肾病与其他肾小球疾病相结合的临床病理分析

获取原文
   

获取外文期刊封面封底 >>

       

摘要

It is not rare to find Immunoglobulin A (IgA) nephropathy (IgAN) combined with other glomerular diseases, which can be called compound IgAN (cIgAN). Till now, clinical-pathological investigation of cIgAN was lacking, especially the severity of “background IgAN lesions.” This research aimed to investigate the incidence, clinical and pathological characteristics of cIgAN, and thus improve the understanding of the clinical significance of this combination. Patients with cIgAN diagnosed in Peking University People's Hospital from November 2012 to April 2018 were retrospectively analyzed. Patients with IgAN without compound glomerular diseases (sIgAN) were enrolled as a control group. Among 1407 patients diagnosed with IgAN, 80 (5.69%) were cIgAN patients. Compared with sIgAN, cIgAN patients had a significantly lower prevalence of microscopic hematuria and more urine protein. There were 10 pathological types of glomerular diseases combined with IgAN, led by diabetic nephropathy 37 (46.25%) and membranous nephropathy 14 (17.5%). Histologically, although the mesangial hypercellularity was comparable in 2 groups, cIgAN patients had a lower prevalence of endocapillary proliferation, segmental glomerulosclerosis, and cellular or fibrocellular crescents formation, as well as weaker immunofluorescence intensity for IgA and C3 (all P .05). Eight out of 27 (29.63%) cIgAN patients with follow-up data (5–48 months) developed irreversible end-stage renal disease requiring dialysis. The order of incidence of concomitant diseases was similar to that of the pure diseases. The “background IgAN associated lesions” except mesangial hypercellularity were relatively mild in cIgAN group. Those might suggest that in some cases, IgAN seems to be a chance finding, and the combined diseases may play a more important role in the clinicopathological features of the patients than the nephritis caused by IgA deposition. While diagnosing IgAN, other combined glomerular diseases need to be carefully considered by nephrologists and pathologists.
机译:寻找免疫球蛋白A(IgA)肾病(IgAn)与其他肾小球疾病联合,可以称为化合物IgAn(CIGAN)并不罕见。到目前为止,缺乏CIGAN的临床病理调查,特别是“背景IGAN病变”的严重程度。该研究旨在探讨CIGAN的发病率,临床和病理特征,从而改善对这种组合的临床意义的理解。回顾性分析了从2012年11月到2018年4月北京大学人民医院诊断的CIGAN患者。没有复合肾小球疾病(SIGAN)的IGAN患者被纳入对照组。在1407名患者中,诊断患有Igan,80例(5.69%)是CIGAN患者。与西南相比,CIGAN患者的微观血尿和更多尿蛋白具有显着降低的患病率。通过糖尿病肾病37(46.25%)和膜状肾病14(17.5%),有10种病理类型的肾小球疾病联合IgAn。组织学上,尽管在2组中具有髓质高纯度相当,但CIGAN患者的内腔增殖,节段性肾小球粥样硬化和细胞或纤维膜细胞,细胞或纤维纤毛或纤维素或纤维纤维素新患者的形成,以及IGA和C3的免疫荧光强度较弱(所有P <.05)。 27例中的八(29.63%)CIGAN患者随访数据(5-48个月)开发了需要透析的不可逆的末期肾病。伴随疾病的发生率与纯疾病的发病率类似。除了髓气高细胞外,“背景IgAn相关病变”在季节性高温性中均为相对轻微。这些可能表明,在某些情况下,Igan似乎是一个机会发现,并且联合疾病可能在患者的临床病理特征中发挥更重要的作用,而不是IgA沉积引起的肾炎。在诊断IgAN时,其他组合的肾小球疾病需要被肾病学家和病理学家仔细考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号